14 results on '"Ravindran, Arun"'
Search Results
2. Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective à long terme avec l'anxiété: une revue systématique et une méta-analyse d'études longitudinales
- Author
-
Xue, Siqi, Husain, M. Ishrat, Zhao, Haoyu, and Ravindran, Arun V.
- Subjects
MARIJUANA abuse ,ANXIETY ,COHORT analysis ,META-analysis ,SYSTEMATIC reviews - Abstract
Copyright of Canadian Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
3. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.
- Author
-
Ravindran, Arun V., Balneaves, Lynda G., Faulkner, Guy, Ortiz, Abigail, McIntosh, Diane, Morehouse, Rachel L., Ravindran, Lakshmi, Yatham, Lakshmi N., Kennedy, Sidney H., Lam, Raymond W., MacQueen, Glenda M., Milev, Roumen V., Parikh, Sagar V., and CANMAT Depression Work Group
- Subjects
- *
MENTAL depression , *THERAPEUTICS , *ALTERNATIVE medicine , *THERAPEUTIC use of meditation , *EVIDENCE-based medicine , *PHOTOTHERAPY , *SLEEP deprivation , *EXERCISE therapy , *BIOTHERAPY , *ACUPUNCTURE , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL protocols , *META-analysis , *RESEARCH , *SYSTEMATIC reviews , *EVALUATION research , *STANDARDS - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Complementary and Alternative Medicine Treatments" is the fifth of six sections of the 2016 guidelines.Results: Evidence-informed responses were developed for 12 questions for 2 broad categories of complementary and alternative medicine (CAM) interventions: 1) physical and meditative treatments (light therapy, sleep deprivation, exercise, yoga, and acupuncture) and 2) natural health products (St. John's wort, omega-3 fatty acids; S-adenosyl-L-methionine [SAM-e], dehydroepiandrosterone, folate, Crocus sativus, and others). Recommendations were based on available data on efficacy, tolerability, and safety.Conclusions: For MDD of mild to moderate severity, exercise, light therapy, St. John's wort, omega-3 fatty acids, SAM-e, and yoga are recommended as first- or second-line treatments. Adjunctive exercise and adjunctive St. John's wort are second-line recommendations for moderate to severe MDD. Other physical treatments and natural health products have less evidence but may be considered as third-line treatments. CAM treatments are generally well tolerated. Caveats include methodological limitations of studies and paucity of data on long-term outcomes and drug interactions. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.
- Author
-
Milev, Roumen V., Giacobbe, Peter, Kennedy, Sidney H., Blumberger, Daniel M., Daskalakis, Zafiris J., Downar, Jonathan, Modirrousta, Mandana, Patry, Simon, Vila-Rodriguez, Fidel, Lam, Raymond W., MacQueen, Glenda M., Parikh, Sagar V., Ravindran, Arun V., and CANMAT Depression Work Group
- Subjects
BRAIN stimulation ,MENTAL depression ,THERAPEUTICS ,TRANSCRANIAL direct current stimulation ,TRANSCRANIAL magnetic stimulation ,ELECTROCONVULSIVE therapy ,DEEP brain stimulation ,EVIDENCE-based medicine ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,META-analysis ,NEURAL stimulation ,RESEARCH ,VAGUS nerve ,SYSTEMATIC reviews ,EVALUATION research ,STANDARDS - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Neurostimulation Treatments" is the fourth of six sections of the 2016 guidelines.Results: Evidence-informed responses were developed for 31 questions for 6 neurostimulation modalities: 1) transcranial direct current stimulation (tDCS), 2) repetitive transcranial magnetic stimulation (rTMS), 3) electroconvulsive therapy (ECT), 4) magnetic seizure therapy (MST), 5) vagus nerve stimulation (VNS), and 6) deep brain stimulation (DBS). Most of the neurostimulation treatments have been investigated in patients with varying degrees of treatment resistance.Conclusions: There is increasing evidence for efficacy, tolerability, and safety of neurostimulation treatments. rTMS is now a first-line recommendation for patients with MDD who have failed at least 1 antidepressant. ECT remains a second-line treatment for patients with treatment-resistant depression, although in some situations, it may be considered first line. Third-line recommendations include tDCS and VNS. MST and DBS are still considered investigational treatments. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
5. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
- Author
-
Kennedy, Sidney H., Lam, Raymond W., McIntyre, Roger S., Tourjman, S. Valérie, Bhat, Venkat, Blier, Pierre, Hasnain, Mehrul, Jollant, Fabrice, Levitt, Anthony J., MacQueen, Glenda M., McInerney, Shane J., McIntosh, Diane, Milev, Roumen V., Müller, Daniel J., Parikh, Sagar V., Pearson, Norma L., Ravindran, Arun V., Uher, Rudolf, and CANMAT Depression Work Group
- Subjects
MENTAL depression ,THERAPEUTICS ,DRUG therapy ,ANTIDEPRESSANTS ,EVIDENCE-based psychiatry ,ANTIPSYCHOTIC agents ,COMORBIDITY ,DRUG side effects ,DRUG interactions - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Pharmacological Treatments" is the third of six sections of the 2016 guidelines. With little new information on older medications, treatment recommendations focus on second-generation antidepressants.Results: Evidence-informed responses are given for 21 questions under 4 broad categories: 1) principles of pharmacological management, including individualized assessment of patient and medication factors for antidepressant selection, regular and frequent monitoring, and assessing clinical and functional outcomes with measurement-based care; 2) comparative aspects of antidepressant medications based on efficacy, tolerability, and safety, including summaries of newly approved drugs since 2009; 3) practical approaches to pharmacological management, including drug-drug interactions and maintenance recommendations; and 4) managing inadequate response and treatment resistance, with a focus on switching antidepressants, applying adjunctive treatments, and new and emerging agents.Conclusions: Evidence-based pharmacological treatments are available for first-line treatment of MDD and for management of inadequate response. However, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
6. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.
- Author
-
Parikh, Sagar V., Quilty, Lena C., Ravitz, Paula, Rosenbluth, Michael, Pavlova, Barbara, Grigoriadis, Sophie, Velyvis, Vytas, Kennedy, Sidney H., Lam, Raymond W., MacQueen, Glenda M., Milev, Roumen V., Ravindran, Arun V., Uher, Rudolf, and CANMAT Depression Work Group
- Subjects
THERAPEUTICS ,MENTAL depression ,EVIDENCE-based psychology ,COGNITIVE therapy ,MINDFULNESS ,BIOPSYCHOSOCIAL model ,PSYCHOTHERAPY - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) has revised its 2009 guidelines for the management of major depressive disorder (MDD) in adults by updating the evidence and recommendations. The target audiences for these 2016 guidelines are psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Psychological Treatments" is the second of six sections of the 2016 guidelines.Results: Evidence-informed responses were developed for 25 questions under 5 broad categories: 1) patient characteristics relevant to using psychological interventions; 2) therapist and health system characteristics associated with optimizing outcomes; 3) descriptions of major psychotherapies and their efficacy; 4) additional psychological interventions, such as peer interventions and computer- and technology-delivered interventions; and 5) combining and/or sequencing psychological and pharmacological interventions.Conclusions: First-line psychological treatment recommendations for acute MDD include cognitive-behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation (BA). Second-line recommendations include computer-based and telephone-delivered psychotherapy. Where feasible, combining psychological treatment (CBT or IPT) with antidepressant treatment is recommended because combined treatment is superior to either treatment alone. First-line psychological treatments for maintenance include CBT and mindfulness-based cognitive therapy (MBCT). Patient preference, in combination with evidence-based treatments and clinician/system capacity, will yield the optimal treatment strategies for improving individual outcomes in MDD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.
- Author
-
MacQueen, Glenda M., Frey, Benicio N., Ismail, Zahinoor, Jaworska, Natalia, Steiner, Meir, Van Lieshout, Ryan J., Kennedy, Sidney H., Lam, Raymond W., Milev, Roumen V., Parikh, Sagar V., Ravindran, Arun V., Lieshout, Ryan J Van, and CANMAT Depression Work Group
- Subjects
DEPRESSION in adolescence ,DEPRESSION in women ,DEPRESSION in old age ,MENTAL depression ,THERAPEUTICS ,EVIDENCE-based psychiatry ,POSTPARTUM depression - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. This section on "Special Populations" is the sixth of six guidelines articles.Results: Recent studies inform the treatment of MDD in children and adolescents, pregnant and breastfeeding women, women in perimenopause or menopause, and the elderly. Evidence for efficacy of treatments in these populations is more limited than for the general adult population, however, and risks of treatment in these groups are often poorly studied and reported.Conclusions: Despite the limited evidence base, extant data and clinical experience suggest that each of these special populations can benefit from the systematic application of treatment guidelines for treatment of MDD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.
- Author
-
Lam, Raymond W., McIntosh, Diane, JianLi Wang, Enns, Murray W., Kolivakis, Theo, Michalak, Erin E., Sareen, Jitender, Wei-Yi Song, Kennedy, Sidney H., MacQueen, Glenda M., Milev, Roumen V., Parikh, Sagar V., Ravindran, Arun V., Wang, JianLi, Song, Wei-Yi, and CANMAT Depression Work Group
- Subjects
MENTAL depression ,THERAPEUTICS ,DEPRESSED persons ,MEDICAL care costs ,SELF-management (Psychology) ,EVIDENCE-based psychiatry ,DIAGNOSIS of mental depression ,MEDICAL care ,EVIDENCE-based medicine ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,MEDICAL societies ,META-analysis ,RESEARCH ,SYSTEMATIC reviews ,EVALUATION research ,STANDARDS - Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. This section is the first of six guidelines articles.Results: In Canada, the annual and lifetime prevalence of MDD was 4.7% and 11.3%, respectively. MDD represents the second leading cause of global disability, with high occupational and economic impact mainly attributable to indirect costs. DSM-5 criteria for depressive disorders remain relatively unchanged, but other clinical dimensions (sleep, cognition, physical symptoms) may have implications for depression management. e-Mental health is increasingly used to support clinical and self-management of MDD. In the 2-phase (acute and maintenance) treatment model, specific goals address symptom remission, functional recovery, improved quality of life, and prevention of recurrence.Conclusions: The burden attributed to MDD remains high, whether from individual distress, functional and relationship impairment, reduced quality of life, or societal economic cost. Applying core principles of care, including comprehensive assessment, therapeutic alliance, support of self-management, evidence-informed treatment, and measurement-based care, will optimize clinical, quality of life, and functional outcomes in MDD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.
- Author
-
Xinyu Zhou, Keitner, Gabor I., Bin Qin, Ravindran, Arun V., Bauer, Michael, Del Giovane, Cinzia, Jingping Zhao, Yiyun Liu, Yiru Fang, Yuqing Zhang, and Peng Xie
- Subjects
ANTIPSYCHOTIC agents ,MENTAL depression ,SYSTEMATIC reviews ,META-analysis ,RANDOMIZED controlled trials - Abstract
Background: Previous meta-analyses of atypical antipsychotics for depression were limited by few trials with direct comparisons between two treatments. We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant depression (TRD). Methods: Systematic searches resulted in 18 RCTs (total n = 4422) of seven different types and different dosages of atypical antipsychotics and a placebo that were included in the review. Results: All standard-dose atypical antipsychotics were significantly more efficacious than placebo in the efficacy (standardized mean differences [SMDs] ranged from -0.27 to -0.43). There were no significant differences between these drugs. Low-dose atypical antipsychotics were not significantly more efficacious than the placebo. In terms of tolerability, all standard-dose atypical antipsychotics, apart from risperidone, had significantly more side-effect discontinuations than placebo (odds ratios [ORs] ranged from 2.72 to 6.40). In terms of acceptability, only quetiapine (mean 250-350 mg daily) had significantly more all-cause discontinuation than placebo (OR = 1.89). In terms of quality of life/functioning, standard-dose risperidone and standard-dose aripiprazole were more beneficial than placebo (SMD = -0.38; SMD = -0.26, respectively), and standard-dose risperidone was superior to quetiapine (mean 250-350 mg daily). Conclusions: All standard-dose atypical antipsychotics for the adjunctive treatment of TRD are efficacious in reducing depressive symptoms. Risperidone and aripiprazole also showed benefits in improving the quality of life of patients. Atypical antipsychotics should be prescribed with caution due to abundant evidence of side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review.
- Author
-
Ravindran, Arun V. and da Silva, Tricia L.
- Subjects
- *
ANXIETY disorders treatment , *SYSTEMATIC reviews , *AFFECTIVE disorders , *MENTAL health services , *META-analysis , *DRUG therapy , *ALTERNATIVE medicine - Abstract
Abstract: Background: Depressed and anxious patients often combine complementary and alternative medicine (CAM) therapies with conventional pharmacotherapy to self-treat symptoms. The benefits and risks of such combination strategies have not been fully evaluated. This paper evaluates the risk-benefit profile of CAM augmentation to antidepressants in affective conditions. Methods: PubMed was searched for all available clinical reports published in English up to December 2012. Data were evaluated based on graded levels of evidence for efficacy and safety. Results: Generally, the evidence base is significantly larger for depression than for anxiety disorder. In unipolar depression, there is Level 2 evidence for adjunctive sleep deprivation (SD) and Free and Easy Wanderer Plus (FEWP), and Level 3 for exercise, yoga, light therapy (LT), omega-3 fatty acids, S-adenosylmethionine and tryptophan. In bipolar depression, there is Level 1 evidence for adjunctive omega-3s, Level 2 for SD, and Level 3 for LT and FEWP. In anxiety conditions, exercise augmentation has Level 3 support in generalized anxiety disorder and panic disorder. Though mostly well-tolerated, these therapies can only be recommended as third-line interventions due to the quality of available evidence. Limitations: Overall, the literature is limited. Studies often had methodological weaknesses, with little information on long-term use and on potential drug–CAM interactions. Many CAM studies were not published in English. Conclusions: While several CAM therapies show some evidence of benefit as augmentation in depressive disorders, such evidence is largely lacking in anxiety disorders. The general dearth of adequate safety and tolerability data encourages caution in clinical use. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
11. Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder.
- Author
-
Bereza, Basil G., Machado, Márcio, Ravindran, Arun V., and Einarson, Thomas R.
- Subjects
EVIDENCE-based medicine ,HEALTH outcome assessment ,DRUG therapy ,GENERALIZED anxiety disorder ,META-analysis ,SEROTONIN uptake inhibitors ,THERAPEUTICS - Abstract
Copyright of Canadian Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
- Full Text
- View/download PDF
12. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis.
- Author
-
Yatham, Megha Sai, Yatham, Kavya Sai, Ravindran, Arun V., and Sullivan, Frank
- Subjects
- *
META-analysis , *RANDOM effects model , *MENTAL depression - Abstract
Background: Clinical trials of the effects of statins in people with and without depressive symptoms at baseline have yielded conflicting results with studies reporting both an increase and decrease in depressive symptoms. To address these inconsistences, a systematic review and meta-analysis has been conducted to determine the effects of statins on depression in those with or without clinical major depression.Methods: A comprehensive literature search was conducted in MEDLINE, EMBASE and PsychINFO to identify relevant articles that met predefined inclusion and exclusion criteria. The primary outcome measure was the mean difference in depression scores at endpoint between the statin and placebo groups which was computed using random effects model.Results: 10 articles were found and used to determine the effects of statins on depressive symptoms. Subgroup analyses were performed to determine the effects of statins in patients with and without depression at baseline. Overall, statin use was associated with significantly lower scores on depression rating scales compared with the placebo use (SMD: -0.309, CI: -0.525, -0.094; p = 0.005). The subgroup analysis showed significant effects in the depressed population (SMD: -0.796, CI: -1.107, -0.486, p = 0.001) but not in the non-depressed population (SMD: -0.153, CI: -0.353, 0.047, p = 0.113).Limitations: There was high heterogeneity in the studies included and only two studies had low risk of bias.Conclusion: The results suggest that statins are effective in improving depressive symptoms, particularly in those with clinical depression and that they do not worsen depression in non-depressed subjects. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Mental health challenges raised by rapid economic and social transformations in China: a systematic review.
- Author
-
Sun, Yankun, Bao, Yanping, Ravindran, Arun, Sun, Yan, Shi, Jie, and Lu, Lin
- Subjects
- *
MENTAL health , *META-analysis , *HEALTH literacy , *MENTAL illness , *NOISE pollution , *UNHEALTHY lifestyles , *MENTAL health laws - Abstract
With the largest proportion of world's total population, the mental health pandemic in China and related challenges of treating mental disorders could influence the accomplishment of UN Sustainable Development Goals, which include mental health. Therefore, understanding China's current mental health status after rapid economic and social transformations, including urbanisation, industrialisation, globalisation and informatisation, could strengthen awareness of mental health, and aid the proposal of solutions to prevent and control mental disorders. We did a systematic search of the literature using PubMed, Embase, PsycINFO, CNKI, and Wanfang databases to find relevant studies published between Jan 1, 1990, and Dec 31, 2018. Articles in English and Chinese were included. The search terms included "urbanisation", "industrialisation", "globalisation", "informatisation", "mental disorders[MeSH Term]" and "China". During the past three decades, both the disease and economic burden of mental disorders have increased in China. Rapid urbanisation and industrialisation have resulted in increasing internal migration and left-behind families, who have poorer mental health status than their peers. The ageing population will lead to higher prevalence of mental and neurological disorders, such as depression and dementia. Adoption of unhealthy diets can directly affect mental health, as well as indirectly by facilitating intermediate risk factors such as obesity. Increased alcohol intake and smoking can induce increased alcohol and nicotine dependence, and even illicit drug abuse. Additionally, internet and social media use can not only increase internet or gaming addiction, but also facilitate exposure and delivery channels via the internet. The growth of urbanisation and manufactories has also increased air, light, and noise pollution that can further induce mental problems. Social and economic transformations have triggered increasing disease and economic burden of mental disorders. We propose three priorities to deal with these challenges: identify social and economic effects on mental health on the basis of high-quality qualitative and quantitative analysis, improve mental health awareness and literacy, and enhance the mental health-care system and promote implementation research. Lessons from China can be a great reference for low-and-middle-income countries (LMICs) and upper-middle-income countries in prevention and control mental disorders. National Natural Science Foundation of China. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
- Author
-
Cipriani, Andrea, Xinyu Zhou, Del Giovane, Cinzia, Hetrick, Sarah E., Bin Qin, Whittington, Craig, Coghill, David, Yuqing Zhang, Hazell, Philip, Leucht, Stefan, Cuijpers, Pim, Juncai Pu, Cohen, David, Ravindran, Arun V., Yiyun Liu, Michael, Kurt D., Lining Yang, Lanxiang Liu, Peng Xie, and Zhou, Xinyu
- Subjects
- *
ANTIDEPRESSANTS , *MENTAL depression , *DEPRESSION in children , *DEPRESSION in adolescence , *PSYCHIATRIC drugs , *DRUG administration , *FLUOXETINE , *HETEROCYCLIC compounds , *IMIPRAMINE , *META-analysis , *PROBABILITY theory , *SERTRALINE , *SYSTEMATIC reviews , *EVIDENCE-based medicine , *TREATMENT effectiveness , *PAROXETINE , *AMITRIPTYLINE , *NORTRIPTYLINE (Drug) , *CITALOPRAM , *CLOMIPRAMINE , *DESIPRAMINE , *CONFOUNDING variables - Abstract
Background: Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.Methods: We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.Findings: We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I(2) values were 33·21% for efficacy and 0% for tolerability.Interpretation: When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.Funding: National Basic Research Program of China (973 Program). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.